Benefits, challenges and obstacles of adaptive clinical trial designs

Orphanet Journal of Rare Diseases

Volumn 6, Issue 1, 2011, Pages

  Chow, Shein Chung ^a   Corey, Ralph ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adaptive dose finding; Efficiency; Flexibility; Group sequential design; Less well understood design; Two stage seamless adaptive design; Well understood design

Indexed keywords

CLINICAL TRIAL (TOPIC); COMPUTER PROGRAM; COMPUTER SIMULATION; DOSE CALCULATION; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; METHODOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; STATISTICAL ANALYSIS; UNITED STATES; ARTICLE; BIOASSAY; DOSE RESPONSE; DRUG INDUSTRY; HUMAN; SAMPLE SIZE; STANDARD; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INDUSTRY; ENDPOINT DETERMINATION; HUMANS; RESEARCH DESIGN; SAMPLE SIZE; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 82255169270     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-6-79     Document Type: Review

References (26)

1. FDA's Critical Path Initiative. Woodcock J, 2004 FDA wesite: http://www.fda.gov/oc/initiatives/criticalpath/woodcock0602/woodcock0602.html
2. Adaptive Design Methods in Clinical Trials. Chow SC, Chang M, Chapman and Hall/CRC Press, Taylor and Francis, New York, New York 2006
3. Adaptive design methods in clinical trials. Chow SC, Chang M, The Orphanet Journal of Rare Diseases 2008 3 11 10.1186/1750-1172-3-11
4. FDA Draft Guidance for Industry-Adaptive Design Clinical Trials for Drugs and Biologics, The United State Food and Drug Administration, Rockville, Maryland. 2010
5. Viewpoints on the FDA draft adaptive designs guidance from the PhRMA Working Group (with discussions). Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J, Journal of Biopharmaceutical Statistics 2010 20 6 1115 1124 10.1080/10543406.2010.514452 21058107
6. Statistical consideration of adaptive methods in clinical development. Chow SC, Chang M, Pong A, Journal of Biopharmaceutical Statistics 2005 15 575 591 10.1081/BIP-200062277 16022164 (Pubitemid 40967300)
7. Adaptive design in clinical drug development-an executive summary of the PhRMA Working Group (with discussions). Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J, Journal of Biopharmaceutical Statistics 2006 16 3 275 283 10.1080/10543400600614742 16724485
8. Point to Consider on Methodological Issues in Confirmatory Clinical Trials with Flexible Design and Analysis Plan. European Medicinal Agency (EMA), The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use. CPMP/EWP/2459/02, London, UK 2002
9. Reflection paper on Methodological Issues in Confirmatory Clinical Trials with Flexible Design and Analysis Plan. European Medicinal Agency (EMA), The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use. CPMP/EWP/2459/02, London, UK 2006
10. Adaptive design method based on sum of p-values. Chang M, Statistics in Medicine 2007 26 2772 2784 10.1002/sim.2755 17133651 (Pubitemid 46865098)
11. A multiple testing procedure for clinical trials. O'Brien PC, Fleming TR, Biometrics 1979 35 549 556 10.2307/2530245 497341 (Pubitemid 10242750)
12. Chow SC, Controversial Statistical Issues in Clinical Trials Chapman and Hall/CRC Press, Taylor and Francis, New York, New York 2011 Chapter 10
13. Implementing adaptive designs: logistical and operational considerations. Quinlan JA, Krams M, Drug Information Journal 2006 40 4 437 444 (Pubitemid 44721121)
14. Adaptive design-what do we know about it? Chow SC, Presented at the CRT 2006 Workshop with the FDA, Arlington, Virginia 2006
15. Adaptive trial design-FDA statistical reviewer's view. Li N, Presented at the CRT 2006 Workshop with the FDA, Arlington, Virginia, April 4, 2006 2006
16. Adaptive trial design-FDA view. Uchida T, Presented at the CRT 2006 Workshop with the FDA, Arlington, Virginia, April 4, 2006 2006
17. Group Sequential Methods. Jennison C, Turnbull BW, Chapman and Hall/CRC Press, New York, New York 1999
18. Adaptive seamless phase II/III designs-background, operational aspects, and examples. Maca J, Bhattacharya S, Dragalin V, Gallo P, Krams M, Drug Information Journal 2006 40 463 474
19. On two-stage seamless adaptive design in clinical trials. Chow SC, Tu YH, Journal of Formosan Medical Association 2008 107 12 51 S59
20. Clinical trial simulation. Li HI, Lai PY, Encyclopedia of Biopharmaceutical Statistics Marcel Dekker, Inc. New York, New York, Chow SC, 2003 200 201
21. Chang M, Monte Carlo Simulation for the Pharmaceutical Industry: Concepts, Algorithms, and Case Studies Chapman and Hall/CRC Press, Taylor & Francis, New York, New York 2010
22. Clinical Trial Design with ExpDesign Studio. CTriSoft Intl, Boston, MA 2002 http://www.ctrisoft.net
23. EastSurvAdapt. Cytel, Inc, Cambridge, MA 2010
24. Pong A, Chow SC, Handbook of Adaptive Designs in Pharmaceutical and Clinical Development Chapman and Hall/CRC Press, Taylor & Francis, New York, New York 2010
25. A brief review on software development for group sequential and adaptive designs. Wassmer G, Vandemeulebroecke M, Biometrical Journal 2006 48 732 737 10.1002/bimj.200510233 16972726 (Pubitemid 44367921)
26. Herson J, Data and Safety Monitoring Committees in Clinical Trials Chapman and Hall/CRC, Boca Raton, Florida 2009